There are currently 1314 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318
Recruiting
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Register for Updates
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Emory Winship Cancer Institute, Atlanta, Georgia
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Register for Updates
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
NCT06204809
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/06/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Myotonic Dystrophy 1
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT05570253
Recruiting
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Emory University (Data Collection Only), Atlanta, Georgia
Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
Register for Updates
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201
Recruiting
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/06/2025
Locations: Emory Children's Center, Atlanta, Georgia
Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease, Type 3, Von Willebrand Disease, Type 2B, Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2 and Type 3
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/06/2025
Locations: Neumora Investigator Site-1, Atlanta, Georgia +2 locations
Conditions: Major Depressive Disorder
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Coronary Artery Disease
Register for Updates
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936
Recruiting
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/06/2025
Locations: Children's Hospital of Atlanta, Atlanta, Georgia
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Register for Updates
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728
Recruiting
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Unresectable Pleural Mesothelioma
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Grady Memorial System, Atlanta, Georgia +2 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates